MOTS-c: A Signal From Inside the Mitochondria

The short version

MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA type-c. It is a 16-amino-acid peptide encoded inside the mitochondrial genome — the small, separate genome carried by the cell's power-generating organelles. That origin is unusual: nearly every other signaling peptide the body makes is encoded in nuclear DNA. MOTS-c's best-understood job is activating AMPK (AMP-activated protein kinase), the cell's master energy sensor, by shutting down a metabolic pathway called the folate cycle in skeletal muscle ^[6]. Exercise raises circulating MOTS-c, and supplementing exogenous MOTS-c improved running capacity, grip strength, and gait in mice from young adults all the way to the old ^[4].

Here is the honest part. The evidence in humans stops well short of efficacy trials. Human data for MOTS-c are observational: circulating MOTS-c levels have been measured and associated with metabolic and cardiovascular outcomes, but no controlled study has given exogenous MOTS-c to humans and measured what happens ^[2][3]. MOTS-c is not an approved drug anywhere; it is prohibited in elite sport; and community claims about fat loss or longevity run far ahead of the clinical evidence. This page summarizes what was studied — it is not advice and lists no human dose.

What it is

MOTS-c is a linear 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR, encoded by a short open reading frame (ORF) within the mitochondrial 12S ribosomal RNA gene (MT-RNR1). It is highly conserved across mammalian species — the sequence is essentially identical in humans and mice — which suggests it performs a fundamental, preserved function rather than a recently evolved one.

Because it is encoded in the mitochondrial genome and secreted into the cytoplasm and bloodstream in response to metabolic stress and exercise, MOTS-c belongs to a class called mitochondrial-derived peptides (MDPs). Other MDPs include humanin and the SHLP family, but MOTS-c is unique in carrying its primary activity in skeletal muscle and in translocating to the nucleus under stress. It is a research peptide with no approved formulation or indication in any regulatory jurisdiction.

How it works

The best-characterized mechanism starts in the folate cycle. MOTS-c inhibits folate-cycle enzymes and thereby blocks de novo purine biosynthesis — the pathway cells use to build purines from scratch. This block causes AICAR (an AMP analogue) to accumulate inside the cell, which activates AMPK. AMPK is the cell's low-energy alarm: when activated, it switches on glucose uptake and fat oxidation while switching off energy-consuming biosynthesis ^[6].

Under metabolic stress, MOTS-c also physically moves from the mitochondrion into the nucleus, where it changes the expression of genes regulated by stress-responsive transcription factors including NRF2 — the first documented case of a mitochondrial-encoded peptide working directly as a retrograde nuclear signal ^[5]. A 2024 study added another layer: MOTS-c directly binds and activates casein kinase 2 (CK2) in a tissue-specific manner, activating CK2 in muscle (helping glucose uptake) while suppressing it in fat tissue ^[1]. The practical picture is a peptide that nudges several arms of energy metabolism at once rather than hitting a single switch.

What the research shows

Founding mechanism and metabolic effects. The paper that identified MOTS-c showed it inhibits the folate cycle and activates AMPK, and demonstrated that MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance and obesity in mice, with skeletal muscle as the primary target organ ^[6].

Exercise-mimetic role. Exercise raises both skeletal-muscle and circulating MOTS-c in mice. Injecting exogenous MOTS-c significantly increased treadmill running capacity, grip strength, and gait across three age groups — 2, 12, and 22 months — with aged mice showing the largest absolute gains (P=0.000002 for running capacity) ^[4]. The authors describe MOTS-c as an exercise-induced mitochondrial regulator of age-dependent physical decline.

Nuclear signaling. Under metabolic stress, MOTS-c translocates from mitochondria to the nucleus and activates antioxidant-response-element (ARE) genes through NRF2 in an AMPK-dependent manner — confirming a retrograde mitochondria-to-nucleus communication route ^[5].

Direct molecular target. A 2024 study in cell-free systems and in young, aged, high-fat-diet, and immobilized mice identified CK2 as a direct binding partner of MOTS-c, with tissue-specific CK2 modulation (activation in muscle, suppression in fat) accounting for effects on muscle glucose uptake and atrophy prevention ^[1].

Human biomarker association. In a prospective multicenter cohort of 94 chronic hemodialysis patients followed for a median of 26.5 months, lower circulating MOTS-c was independently associated with a composite endpoint of all-cause mortality and non-fatal cardiovascular events, and adding MOTS-c improved the predictive model's discrimination from AUC 0.727 to 0.743 ^[2]. This is among the strongest human clinical-association data for MOTS-c — but it is observational, not interventional.

Cardiac metabolic model. In rats with a type-2-diabetes model (high-fat diet plus streptozotocin), MOTS-c treatment increased oxidative phosphorylation respiration in cardiac mitochondria and was associated with reduced fasting glucose and reduced left-ventricular hypertrophy ^[7].

Review context. A 2023 review synthesizes MOTS-c biology across metabolic, stress-adaptive, and aging pathways, consolidating its MT-RNR1 origin, AMPK/folate-cycle mechanism, exercise inducibility, and nuclear translocation as an integrated picture ^[3].

Reported effects, cautions & safety

Several cautions follow directly from the published record:

• No human efficacy trials. Every claim about exogenous MOTS-c improving metabolism, performance, or aging markers comes from cell or animal studies. Human data are observational biomarker associations, not interventional outcomes ^[3].
• No validated human pharmacokinetics. There is no published, measured human half-life, bioavailability, or dose-response for MOTS-c. Rodent doses used in research (0.5–15 mg/kg/day) cannot be extrapolated to humans.
• Research-chemical status. MOTS-c is sold only for laboratory research and is not regulated as a pharmaceutical. Product purity, identity, and sterility are not subject to approved-drug oversight ^[3].
• Anti-doping prohibition. MOTS-c is prohibited in elite sport; anti-doping bodies (USADA/WADA) classify it under peptide/metabolic-modulator categories prohibited at all times. Athletes face sanctions for use.
• Genotype interactions. A pro-diabetogenic mitochondrial variant (m.1382A>C) and ancestry-dependent exercise responses in human populations suggest MOTS-c effects are not uniform across individuals.
• Single-lab reliance for some findings. Several mechanistic conclusions await broad independent replication.

MOTS-c has no published community-anecdote or clinical-use safety reports to draw on; none are presented here.

Where it fits in metabolic research

MOTS-c is the lead on this desk and the more unusual of the two peptides — not because its evidence is stronger, but because its origin is: encoded in mitochondria, released in response to exercise, linking the cell's power stations to systemic metabolism and even nuclear gene expression. That story is coherent and compelling across preclinical work ^[1][4][5][6]. What it lacks is an interventional human study of any kind. Placed alongside tesamorelin — which has completed Phase 3 RCTs — MOTS-c illustrates the gap between a well-mechanized preclinical signal and clinical translation. See the comparison page for how they line up.